Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology, Inc. (Nasdaq: NXL), a leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™), announced the issuance of U.S. Patent No. 12,629,519 on June 4, 2026. The patent covers its transcranial alternating current dynamic frequency stimulation method for treating anxiety, depression, and insomnia, three major unmet medical needs in mental health. The patent provides U.S. intellectual property protection through 2042, reinforcing Nexalin’s competitive position in frequency-based deep-brain neurostimulation. It expands the company’s patent portfolio, which supports its HALO™ Clarity and NeuroCare™ strategies, designed for physician-supervised, drug-free, non-invasive mental health treatment administered at home. Nexalin’s DIFS™ platform targets deeper brain structures linked to neuropsychiatric conditions, offering an alternative to traditional medications and clinic-based treatments. The patent covers methods for dynamic frequency stimulation delivered through transcranial alternating current, aligning with the company’s broader clinical and commercial goals. CEO Mark White stated the patent strengthens Nexalin’s long-term platform strategy, validating its deep-brain frequency stimulation approach. The company plans to leverage its expanding patent estate to support clinical development, regulatory progress, and commercialization of its AI-enabled virtual care platform. The patent also builds on Nexalin’s intellectual property strategy for other neurological indications, including Alzheimer’s disease, traumatic brain injury (TBI), and PTSD. The company believes this foundation will drive product differentiation and exclusivity in large markets. Nexalin’s NeuroCare™ virtual clinic model aims to provide scalable, in-home mental health solutions, potentially creating a new category of non-invasive, deep-brain treatments.